CA
NZ
UK
AU
IND
US
BiomX is a clinical-stage company developing natural and engineered phage therapies, viruses that selectively target and kill specific bacteria. Its lead candidate, BX004, is being studied in a Phase 2b trial for chronic Pseudomonas aeruginosa lung infections in patients with cystic fibrosis, a difficult-to-treat …
Senti Biosciences is a clinical-stage company built around "logic-gated" cell and gene therapies, using engineered gene circuits designed to help therapies distinguish cancer cells from healthy tissue. Its most advanced asset, SENTI-202, is an allogeneic CAR-NK cell therapy aimed at acute myeloid leukemia and …
Core One Labs is a research-and-development company focused on psychedelic medicine, including biosynthetic production of psilocybin and delivery-technology platforms, alongside interests spanning natural health products and medical clinics. Its shares historically traded in Canada on theCanadian Securities Exchange (CSE)and in the U.S. over-the-counter market. …
Nano-X Imaging develops digital X-ray and medical-imaging technology, most notably the Nanox.ARC, a multi-source tomosynthesis system built around its cold-cathode digital X-ray source, along with AI-based image-analysis applications and a teleradiology arm. Through 2026 the company has focused on commercialising that hardware and software. …
22nd Century Group manufactures, distributes and sells proprietary reduced-nicotine tobacco products and provides contractManufacturingfor other tobacco brands. Its flagship is VLN, a cigarette engineered to contain far less nicotine, marketed under an FDA Modified Risk Tobacco Product framework as a harm-reduction option. Through 2026 …
GeoVax, based in Atlanta, develops vaccines and immunotherapies using its Modified Vaccinia Ankara (MVA) platform. On August 27, 2026, the company disclosed it had received a delisting determination from Nasdaq. According to its subsequent 8-K, GOVX's closing bid price stayed below the $1.00 minimum …
Reviva is a clinical-stage pharmaceutical company focused on brilaroxazine, an investigational treatment for schizophrenia and other central-nervous-system and inflammatory conditions. A notable structural development came on May 14, 2026, when Reviva's common stock moved from the Nasdaq Capital Market to the OTCQB Venture Market, …
Vaxxinity is a biotechnology company that built a platform aimed at turning chronic-disease treatment toward vaccine-like immunotherapies, historically targeting neurodegenerative conditions such as Parkinson's and Alzheimer's disease. The pivotal corporate development for the stock came in April 2024, when Vaxxinity announced its intention to …
On September 10, 2025, MEI Pharma announced it had rebranded as Lite Strategy, Inc. and adopted the newNasdaqticker LITS. The move accompanied a strategic overhaul: the company closed a $100 million private placement in July 2025 to fund a digital-asset treasury built around Litecoin …
Biomolecular Life Holdings is a small over-the-counter company positioning itself in the wellness and longevity space,Marketingpremium supplements it describes as developed using nutrigenomics and artificial intelligence, alongside services spanning precision nutrition and regenerative wellness technologies. The corporate history matters here: the entity traces back …
Please wait processing your request...